GAIN THERAPEUTICS, INC Foreign Currency Transaction Gain (Loss), Unrealized
GAIN THERAPEUTICS, INC (GANX) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$72.37 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-11
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$72.37K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$188.16K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was $36.79K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $37.06K, a 161.14% increase year-over-year.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$619.80K, a 5245.70% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), unrealized for fiscal 2024 was $12.04K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$72.37K 10-Q · filed 2026-08-11 | -$260.54K 10-Q · filed 2026-08-11 | -$223.75K derived: sum of 3 quarters · filed 2026-08-11 | -$186.68K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$188.16K 10-Q · filed 2026-05-11 | -$151.37K derived: sum of 2 quarters · filed 2026-05-11 | -$114.31K derived: sum of 3 quarters · filed 2026-05-11 | -$741.07K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $36.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $73.86K derived: sum of 2 quarters · filed 2026-03-26 | -$552.90K derived: sum of 3 quarters · filed 2026-08-11 | -$619.80K 10-K · filed 2026-03-26 |
| 2025-09-30 | $37.06K 10-Q · filed 2025-11-12 | -$589.69K derived: sum of 2 quarters · filed 2026-08-11 | -$656.59K 10-Q · filed 2025-11-12 | -$668.54K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$626.76K 10-Q · filed 2026-08-11 | -$693.65K 10-Q · filed 2026-08-11 | -$705.61K derived: sum of 3 quarters · filed 2026-08-11 | -$691.41K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$66.90K 10-Q · filed 2026-05-11 | -$78.85K derived: sum of 2 quarters · filed 2026-05-11 | -$64.66K derived: sum of 3 quarters · filed 2026-05-11 | -$194.95K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$11.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.24K derived: sum of 2 quarters · filed 2026-03-26 | -$128.05K derived: sum of 3 quarters · filed 2026-03-26 | $12.04K 10-K · filed 2026-03-26 |
| 2024-09-30 | $14.19K 10-Q · filed 2025-11-12 | -$116.10K derived: sum of 2 quarters · filed 2025-11-12 | $24.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$130.29K 10-Q · filed 2025-08-12 | $9.80K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |